Akero Therapeutics Stock Performance
| AKRO Stock | USD 48.51 1.04 2.19% |
Akero Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.8, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Akero Therapeutics will likely underperform. Use Akero Therapeutics standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to analyze future returns on Akero Therapeutics.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Akero Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Akero Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.29) | Five Day Return (7.75) | Year To Date Return 69.05 | Ten Year Return 159.12 | All Time Return 159.12 |
1 | Disposition of 10000 shares by Young Jonathan of Akero Therapeutics at 32.131 subject to Rule 16b-3 | 12/02/2024 |
2 | Disposition of 7855 shares by Cheng Andrew of Akero Therapeutics at 30.79 subject to Rule 16b-3 | 12/10/2024 |
3 | Acquisition by Cheng Andrew of 295600 shares of Akero Therapeutics at 29.23 subject to Rule 16b-3 | 12/16/2024 |
4 | Disposition of 3800 shares by Timothy Rolph of Akero Therapeutics at 19.87 subject to Rule 16b-3 | 12/17/2024 |
5 | Acquisition by Timothy Rolph of 3800 shares of Akero Therapeutics at 19.87 subject to Rule 16b-3 | 12/24/2024 |
6 | Disposition of 14100 shares by Timothy Rolph of Akero Therapeutics subject to Rule 16b-3 | 12/26/2024 |
7 | Disposition of 10000 shares by Young Jonathan of Akero Therapeutics at 28.033 subject to Rule 16b-3 | 01/02/2025 |
8 | Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/07/2025 |
9 | Disposition of 50000 shares by Cheng Andrew of Akero Therapeutics at 0.615 subject to Rule 16b-3 | 01/23/2025 |
10 | Acquisition by Young Jonathan of 43064 shares of Akero Therapeutics at 6.364 subject to Rule 16b-3 | 01/24/2025 |
11 | Akeros Stock Skyrockets 112 percent After Game-Changing Liver Drug Data | 01/27/2025 |
12 | Disposition of 16264 shares by Timothy Rolph of Akero Therapeutics at 21.1 subject to Rule 16b-3 | 01/29/2025 |
13 | Akero Therapeutics Inc Completes 402.5 Million Public Offering | 01/30/2025 |
14 | Akero Therapeutics Inc. Among The Stocks That Started The Year On A High | 02/03/2025 |
15 | Why Akero Therapeutics Inc Is Skyrocketing So Far In 2025 | 02/04/2025 |
16 | Disposition of 200 shares by Cheng Andrew of Akero Therapeutics at 55.81 subject to Rule 16b-3 | 02/10/2025 |
17 | RTW INVESTMENTS, LP Increases Stake in Akero Therapeutics Inc | 02/14/2025 |
18 | Disposition of 10000 shares by Catriona Yale of Akero Therapeutics at 21.1 subject to Rule 16b-3 | 02/18/2025 |
19 | Akero Therapeutics, Inc. the Best Performing Healthcare Stock So Far in 2025 | 02/19/2025 |
| Begin Period Cash Flow | 249.9 M | |
| Free Cash Flow | -145.4 M |
Akero |
Akero Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,210 in Akero Therapeutics on November 28, 2024 and sell it today you would earn a total of 1,537 from holding Akero Therapeutics or generate 47.88% return on investment over 90 days. Akero Therapeutics is currently generating 1.2351% in daily expected returns and assumes 13.2636% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Akero, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Akero Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Akero Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Akero Therapeutics, and traders can use it to determine the average amount a Akero Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0931
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AKRO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.26 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.24 actual daily | 24 76% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Akero Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Akero Therapeutics by adding it to a well-diversified portfolio.
Akero Therapeutics Fundamentals Growth
Akero Stock prices reflect investors' perceptions of the future prospects and financial health of Akero Therapeutics, and Akero Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Akero Stock performance.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 3.1 B | ||||
| Shares Outstanding | 76.23 M | ||||
| Price To Earning | (7.43) X | ||||
| Price To Book | 5.12 X | ||||
| EBITDA | (148.63 M) | ||||
| Net Income | (151.76 M) | ||||
| Cash And Equivalents | 180.72 M | ||||
| Cash Per Share | 4.81 X | ||||
| Total Debt | 26.3 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 10.61 X | ||||
| Cash Flow From Operations | (145.37 M) | ||||
| Earnings Per Share | (3.78) X | ||||
| Market Capitalization | 3.62 B | ||||
| Total Asset | 580.27 M | ||||
| Retained Earnings | (574.1 M) | ||||
| Working Capital | 540.83 M | ||||
| Current Asset | 22.85 M | ||||
| Current Liabilities | 859.05 K | ||||
About Akero Therapeutics Performance
By examining Akero Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Akero Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Akero Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.28) | (0.29) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.33) | (0.31) |
Things to note about Akero Therapeutics performance evaluation
Checking the ongoing alerts about Akero Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Akero Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Akero Therapeutics is way too risky over 90 days horizon | |
| Akero Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (151.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Akero Therapeutics currently holds about 180.72 M in cash with (145.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.81. | |
| Akero Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Akero Therapeutics, Inc. the Best Performing Healthcare Stock So Far in 2025 |
- Analyzing Akero Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Akero Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Akero Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Akero Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Akero Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Akero Therapeutics' stock. These opinions can provide insight into Akero Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.